Bipolar disorder as cell membrane dysfunction. Progress toward integrative management

Alternative Medicine Review

Volumn 9, Issue 2, 2004, Pages 107-135

  Kidd, Parris M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4,5 TRICHLOROPHENOXYACETIC ACID; ALPHA TOCOPHEROL; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CLONAZEPAM; DOCOSAHEXAENOIC ACID; FLUOXETINE; GUANINE NUCLEOTIDE BINDING PROTEIN; LAMOTRIGINE; LINSEED OIL; LITHIUM; MULTIVITAMIN; NIMODIPINE; OLANZAPINE; OMEGA 3 FATTY ACID; PHOSPHATIDYLCHOLINE; RISPERIDONE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPTOPHAN; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL; VITAMIN B GROUP;

ACNE; ADOLESCENT; ADULT; ATAXIA; BEHAVIOR THERAPY; BIPOLAR DISORDER; BLOOD DYSCRASIA; CARDIOTOXICITY; CELL MEMBRANE; CHILD; CLINICAL ARTICLE; COGNITIVE DEFECT; COGNITIVE THERAPY; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIET SUPPLEMENTATION; DRUG EFFICACY; DYSARTHRIA; ELECTROCONVULSIVE THERAPY; ENVIRONMENTAL EXPOSURE; EOSINOPHILIA MYALGIA SYNDROME; FAMILY HISTORY; GASTROINTESTINAL TOXICITY; GENETIC SUSCEPTIBILITY; GOITER; HAIR LOSS; HUMAN; HYPOTHYROIDISM; LIVER TOXICITY; MANIA; MENTAL DISEASE; MYOCLONUS; NAUSEA; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OVARY POLYCYSTIC DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; POLYURIA; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PSYCHIATRIC DIAGNOSIS; PSYCHOPHARMACOTHERAPY; REVIEW; RISK FACTOR; SEDATION; SEROTONIN SYNDROME; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOMNOLENCE; STEVENS JOHNSON SYNDROME; STRESS; SUBSTANCE ABUSE; TASTE DISORDER; TERATOGENICITY; TREMOR; VITAMIN DEFICIENCY; WEIGHT GAIN;

ADOLESCENT; ADULT; BIPOLAR DISORDER; CELL MEMBRANE; CHILD; HUMANS; NIMODIPINE; PSYCHOTHERAPY; PSYCHOTROPIC DRUGS; SIGNAL TRANSDUCTION;

EID: 3042595032     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (142)

1. Moller HJ. Bipolar disorder and schizophrenia: distinct illnesses or a continuum? J Clin Psychiatr 2003;64:23-27.
2. Child and Adolescent Bipolar Foundation. Child psychiatry researchers from Washington University School of Medicine in St. Louis report bipolar disorder in children appears more severe than in most adults. Child and Adolescent Bipolar Foundation (CABF); 2002. wwwbpkids.org.
3. Kluger J, Song S. Young and bipolar. Time 2002;160:38-46,51.
4. Moller HJ, Nasrallah HA. Treatment of bipolar disorder. J Clin Psychiatry 2003;64:9-17.
5. Hirschfeld RM, Calabrese JR, Weissman MM, et al. Screening for bipolar disorder in the community. J Clin Psychiatry 2003;64:53-59.
6. Oepen G, Baldessarini RJ, Salvatore P. On the periodicity of manic-depressive insanity, by Eliot Slater (1938): translated excerpts and commentary. J Affect Disord 2004;78:1-9.
7. Rush AJ. Bipolar disorder: origin, recognition, and treatment. J Clin Psychiatry 2003;64:3.
8. Child and Adolescent Bipolar Foundation. About early-onset bipolar disorder. Child and Adolescent Bipolar Foundation (CABF); 2002. wwwbpkids.org.
9. Rush AJ. Toward an understanding of bipolar disorder and its origin. J Clin Psychiatry 2003;64:4-8.
10. American Psychiatric Association. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association; 2000.
11. Kaplan A. Experts reach "extraordinary" consensus on bipolar disorder. Psychiatric Times, online. Child and Adolescent Bipolar Foundation (CABF);2000. wwwbpkidsorg.
12. Freeman MP, Freeman SA, McElroy SL. The comorbidity of bipolar and anxiety disorders: prevalence, psychobiology, and treatment issues. J Affect Disord 2002;68:1-23.
13. Wozniak J, Crawford MH, Biederman J, et al. Antecedents and complications of trauma in boys with ADHD: findings from a longitudinal study. J Am Acad Child Adolesc Psychiatry 1999;38:48-55.
14. Horrobin DF, Bennett CN. Depression and bipolar disorder: relationships to impaired fatty acid and phospholipid metabolism and to diabetes, cardiovascular disease, immunological abnormalities, cancer, ageing and osteoporosis. Possible candidate genes. Prostaglandins Leukot Essent Fatty Acids 1999;60:217-234.
15. Goodwin RD, Jacobi F, Thefeld W. Mental disorders and asthma in the community. Arch Gen Psychiatry 2003;60:1125-1130.
16. Low NC, Merikangas KR. The comorbidity of migrane. CNS Spectr 2003;8:433-434,437-444.
17. Yatham LN, Srisurapanont M, Zis AP, Kusumakar V. Comparative studies of the biological distinction between unipolar and bipolar depressions. Life Sci 1997;61:1445-1455.
18. Horrobin DF, Bennett CN. New gene targets related to schizophrenia and other psychiatric disorders: enzymes, binding proteins and transport proteins involved in phospholipid and fatty acid metabolism. Prostaglandins Leukot Essent Fatty Acids 1999;60:141-167.
19. Kendell RE. Diagnosis and classification of functional psychoses. Br Med Bull 1987;43:499-513.
20. Harrison PJ. The neuropathology of primary mood disorder. Brain 2002;125:1428-1449.
21. Yildiz A, Sachs GS, Dorer DJ, Renshaw PF. 31P Nuclear magnetic resonance spectroscopy findings in bipolar illness: a meta-analysis. Psychiatr Res 2001;106:181-191.
22. Stoll AL, Renshaw PF, Yurgelun-Todd DA, Cohen BM. Neuroimaging in bipolar disorder: what have we learned? Biol Psychiatry 2000;48:505-517.
23. Vawter MP, Freed WJ, Kleinman JE. Neuropathology of bipolar disorder. Biol Psychiatry 2000;48:486-504.
24. Drevets WC, Price JL, Simpson JR Jr, et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature 1997;386:824-827.
25. Ongur D, Drevets WC, Price JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci U S A 1998;95:13290-13295.
26. Rosoklija G, Toomayan G, Ellis SP, et al. Structural abnormalities of subicular dendrites in subjects with schizophrenia and mood disorders: preliminary findings. Arch Gen Psychiatry 2000;57:349-356.
27. Ketter TA, Drevets WC. Neuroimaging studies of bipolar depression: functional neuropathology, treatment effects, and predictors of clinical response. Clin Neurosci Res 2002;2:182-192.
28. Mayberg HS. Limbic-cortical dysregulation: a proposed model of depression. J Neuropsychiatry Clin Neurosci 1997;9:471-481.
29. Ketter TA, Kimbrell TA, George MS, et al. Effects of mood and subtype on cerebral glucose metabolism in treatment-resistant bipolar disorder. Biol Psychiatry 2001;49:97-109.
30. Hamakawa H, Kato T, Murashita J, Kato N. Quantitative proton magnetic resonance spectroscopy of the basal ganglia in patients with affective disorders. Eur Arch Psychiatry Clin Neurosci 1998;248:53-58.
31. Modica-Napolitano JS, Renshaw PF. Ethanolamine and phosphoethanolamine inhibit mitochondrial function in vitro: implications for mitochondrial dysfunction hypothesis in depression and bipolar disorder. Biol Psychiatry 2004;55:273-277.
32. Moore GJ, Bebchuck JM, Hasanat K, et al. Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2′s neurotrophic effects? Biol Psychiatry 2000;48:1-8.
33. Moore GJ, Bebchuck JM, Wilds IB, et al. Lithium-induced increase in human brain grey matter. Lancet 2000;356:1241-1242.
34. Kato T, Kato N. Mitochondrial dysfunction in bipolar disorder. Bipolar Disord 2000;2:180-190.
35. Kato T, Murashita J, Kamiya A, et al. Decreased brain intracellular pH measured by 31P-MRS in bipolar disorder: a confirmation in drug-free patients and correlation with white matter hyperintensity. Eur Arch Psychiatry Clin Neurosci 1998;248:301-306.
36. Post RM, Leverich GS, Xing G, Weiss RB. Developmental vulnerabilities to the onset and course of bipolar disorder. Dev Psychopathol 2001;13:581-598.
37. van Os J, Jones P, Lewis G, et al. Developmental precursors of affective illness in a general population birth cohort. Arch Gen Psychiatry 1997;54:625-631.
38. Edwards HE, Dortok D, Tam J, et al. Prenatal stress alters seizure thresholds and the development of kindled seizures in infant and adult rats. Horm Behav 2002;42:437-447.
39. Cavanagh JT, Van Beck M, Muir W, Blackwood DH. Case-control study of neurocognitive function in euthymic patients with bipolar disorder: an association with mania. Br J Psychiatry 2002;180:320-326.
40. Geller B, Luby J. Child and adolescent bipolar disorder: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry 1997;36:1168-1176.
41. Murray MT. Lifestyle and dietary factors in depression. Am J Natural Med 1995;2:10-15.
42. Lishman WA. The psychiatric sequelae of head injury: a review. Psychol Med 1973;3:304-318.
43. Wu A, Molteni R, Ying Z, Gomez-Pinilla F. A saturated-fat diet aggravates the outcome of traumatic brain injury on hippocampal plasticity and cognitive function by reducing brain-derived neurotrophic factor. Neuroscience 2003;119:365-375.
44. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264:2511-2518.
45. Winokur G, Turvey C, Akiskal H, et al. Alcoholism and drug abuse in three groups - bipolar I, unipolars and their acquaintances. J Affect Disord 1998;50:81-89.
46. Burkett G, Yasin S, Palow D. Perinatal implications of cocaine exposure. J Reprod Med 1990;35:35-42.
47. Robinowitz R, Roberts WR, Dolan MP, et al. Carcinogenicity and teratogenicity vs. psychogenicity: psychological characteristics associated with self-reported Agent Orange exposure among Vietnam combat veterans who seek treatment for substance abuse. J Clin Psychol 1989;45:718-728.
48. Angst J, Sellaro R. Historical perspectives and natural history of bipolar disorder. Biol Psychiatry 2000;48:445-457.
49. Haddad P, Dursun S. Pharmacological management of bipolar depression. Acta Psychiatr Scand 2002;105:401-403.
50. MacQueen GM, Young LT, Joffe RT. A review of psychosocial outcome in patients with bipolar disorder. Arch Psychiatr Scand 2001;103:163-170.
51. Gitlin MJ, Swendsen J, Heller TL, Hammen C. Relapse and impairment in bipolar disorder. Am J Psychiatry 1995;152:1635-1640.
52. Otto MW, Reilly-Harrington N, Sachs GS. Psychoeducational and cognitive-behavioral strategies in the management of bipolar disorder. J Affect Disord 2003;73:171-181.
53. Kidd PM. Dietary phospholipids as anti-aging nutraceuticals. In: Klatz RA, Goldman R, eds. Anti-Aging Medical Therapeutics, Volume IV. Chicago, IL: Health Quest Publications; 2000.
54. Stoll AL, Locke CA, Marangell LB, Severus WE. Omega-3 fatty acids and bipolar disorder: a review. Prostaglandins Leukot Essent Fatty Acids 1999;60:329-337.
55. Shelton MD. Treating bipolar depression: newly diagnosed patients may resist taking a mood stabilizer, but the cycling-not just the depression-requires treatment. J Fam Pract 2003;52:s14-s20
56. Cowdry RW, Wehr TA, Zis AP, Goodwin FK. Thyroid abnormalities associated with rapidcycling bipolar illness. Arch Gen Psychiatry 1983;40:414-420.
57. Stancer HC, Persad E. Treatment of intractable rapid-cycling manic-depressive disorder with levothyroxine. Clinical observations. Arch Gen Psychiatry 1982;39:311-312.
58. Pelton R, LaValle JB. The Nutritional Cost of Prescription Drugs. Englewood, CO: Morton Publishing Company; 2000.
59. Lazarus JH. The effects of lithium therapy on thyroid and thyrotropin-releasing hormone. Thyroid 1998;8:909-913.
60. Tohen M, Vieta E, Ketter T, et al. Olanzapine and olanzapine-fluoxetine combination (OFC) in the treatment of bipolar depression. American Psychiatric Association Annual Meeting. Philadelphia, PA; 2002.
61. Salama AA, Shafey M. A case of severe lithium toxicity induced by combined fluoxetine and lithium carbonate. Am J Psychiatry 1989;146:278.
62. Sovner R, Davis JM. A potential drug interaction between fluoxetine and valproic acid. J Clin Psychopharmacol 1991;11:389.
63. Gernaat HB, Van de Woude J, Touw DJ. Fluoxetine and parkinsonism in patients taking carbamazepine. Am J Psychiatry 1991;148:1604-1605.
64. Kaufman KR, Gerner R. Lamotrigine toxicity secondary to sertraline. Seizure 1998;7:163-165.
65. Koczerginski D, Kennedy SH, Swinson RP. Clonazepam and lithium - a toxic combination in the treatment of mania? Intl Clin Psychopharmacol 1989;4:195-199.
66. Sachs G, Printz DJ, Kahn DA, et al. Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder, 2000. www.psychguides.com.
67. Bloch Y, Levcovitch Y, Bloch AM, et al. Electroconvulsive therapy in adolescents: similarities to and differences from adults. J Am Acad Child Adolesc Psychiatry 2001;40:1332-1336.
68. Taieb O, Cohen D, Mazet P, Flament M. Adolescents' experiences with ECT. J Am Acad Child Adolesc Psychiatry 2000;39:943-944.
69. Sackeim HA, Freeman J, McElhiney M, et al. Effects of major depression on estimates of intelligence. J Clin Exp Neuropsychol 1992;14:268-288.
70. Burt T, Lisanby SH, Sackeim HA. Neuropsychiatric applications of transcranial magnetic stimulation: a meta analysis. Intl J Neuropsychopharmacol 2002;5:73-103.
71. Erfurth A, Michael N, Mostert C, Arolt V. Euphoric mania and rapid transcranial magnetic stimulation. Am J Psychiatry 2000;157:835-836.
72. Fields A, Li PP, Kish SJ, Warsh JJ. Increased cyclic AMP-dependent protein kinase activity in postmortem brain from patients with bipolar affective disorder. J Neurochem 1999;73:1704-1710.
73. Wang HY, Friedman E. Enhanced protein kinase C activity and translocation in bipolar affective disorder brains. Biol Psychiatry 1996;40:568-575.
74. Wang HY, Friedman E. Lithium inhibition of protein kinase C activation-induced serotonin release. Psychopharmacology (Berl) 1989;99:213-218.
75. Pacheco MA, Jope RS. Phosphoinositide signaling in human brain. Prog Neurobiol 1996;50:255-273.
76. Soares JC, Dippold CS, Wells KF, et al. Increased platelet membrane phosphatidylinositol-4,5-bisphosphate in drug-free depressed bipolar patients. Neurosci Lett 2001;299:150-152.
77. Brown AS, Mallinger AG, Renbaum LC. Elevated platelet membrane phosphatidylinositol-4,5-bisphosphate in bipolar mania. Am J Psychiatry 1993;150:1252-1254.
78. Dubovsky SL, Murphy J, Christiano J, Lee C. The calcium second messenger system in bipolar disorders: data supporting new research directions. J Neuropsychiatry Clin Neurosci 1992;4:3-14.
79. Soares JC, Mallinger AG. Abnormal phosphatidylinositol (PI)-signalling in bipolar disorder. Biol Psychiatry 1996;39:461-464.
80. Dubovsky SL, Christiano J, Daniell LC, et al. Increased platelet intracellular calcium concentration in patients with bipolar affective disorders. Arch Gen Psychiatry 1989;46:632-638.
81. Soares JC, Mallinger AG, Dippold CS, et al. Effects of lithium on platelet membrane phosphoinositides in bipolar disorder patients: a pilot study. Psychopharmacology (Berl) 2000;149:12-16.
82. Friedman E, Hoau-Yan-Wang, Levinson D, et al. Altered platelet protein kinase C activity in bipolar affective disorder, manic episode. Biol Psychiatry 1993;33:520-525.
83. Wang HY, Markowitz P, Levinson D, et al. Increased membrane-associated protein kinase C activity and translocation in blood platelets from bipolar affective disorder patients. J Psychiatr Res 1999;33:171-179.
84. Chen G, Manji HK, Hawver DB, et al. Chronic sodium valproate selectively decreases protein kinase C alpha and epsilon in vitro. J Neurochem 1994;63:2361-2364.
85. Atack JR. Inositol monophosphatase inhibitors: a novel treatment for bipolar disorder? Biol Psychiatry 1995;37:761-763.
86. Chang MC, Jones CR. Chronic lithium treatment decreases brain phospholipase A2 activity. Neurochem Res 1998;23:887-892.
87. Hibbeln JR, Palmer JW, Davis JM. Are disturbances in lipid-protein interactions by phospholipase-A2 a predisposing factor in affective illness? Biol Psychiatry 1989;25:945-961.
88. Mandell AJ. Non-equilibrium behavior of some brain enzyme and receptor systems. Annu Rev Pharmacol Toxicol 1984;24:237-274.
89. Potter WZ, Rudorfer MV, Goodwin FK. Biological findings in bipolar disorders. In: Hales RE, Frances AJ, eds. American Psychiatric Association Annual Review, Volume 6. Washington, DC: APA; 1987.
90. Abdulla YH, Hamadah K. Effect of ADP on PGE1 formation in blood platelets from patients with depression, mania and schizophrenia. Br J Psychiatry 1975;127:591-595.
91. Stoll AL, Severus WE, Freeman MP, et al. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999;56:407-412.
92. Rudin DO. The major psychoses and neuroses as omega-3 essential fatty acid deficiency syndrome: substrate pellagra. Biol Psychiatry 1981;16:837-850.
93. Rudin DO, Felix C. Omega-3 Oils: To Improve Mental Health, Fight Degenerative Diseases, and Extend Your Life. New York, NY: Avery Publishing; 1996.
94. Martinez M, Mougan I. Fatty acid composition of human brain phospholipids during normal development. J Neurochem 1998;71:2528-2533.
95. Bjerve KS, Fischer S, Wammer F, Egeland T. Alpha-linolenic and long-chain omega-3 fatty acid supplementation in three patients with omega-3 fatty acid deficiency: effect on lymphocyte function, plasma and red cell lipids, and prostanoid formation. Am J Clin Nutr 1989;49:290-300.
96. th ed. New York, NY: Garland Science; 2002.
97. Holian O, Nelson R. Action of long-chain fatty acids on protein kinase C activity: comparison of omega-6 and omega-3 fatty acids. Anticancer Res 1992;12:975-980.
98. Ascherio A, Rimm EB, Stampfer MJ, et al. Dietary intake of marine n-3 fatty acids, fish intake, and the risk of coronary disease among men. N Engl J Med 1995;332:977-982.
99. Watson G, Currier WD. Intensive vitamin therapy in mental illness. J Psychol 1960;49:67-81.
100. Braverman ER, Pfeiffer CC. The Healing Nutrients Within: Facts, Findings and New Research on Amino Acids. New Canaan, CT: Keats Publishing; 1987.
101. Cohen BM, Miller AL, Lipinski JF, Pope HG. Lecithin in mania: a preliminary report. Am J Psychiatry 1980;137:242-243.
102. Cohen BM, Lipinski JF, Altesman RI. Lecithin in the treatment of mania: double-blind, placebo-controlled trials. Am J Psychiatry 1982;139:1162-1164.
103. Schreier HA. Mania responsive to lecithin in a 13-year-old girl. Am J Psychiatry 1982;139:108-110.
104. Ehrlich BE, Diamond JM. Lithium, membranes, and manic-depressive illness. J Membr Biol 1980;52:187-200.
105. Lachman HM, Papolos DF. Abnormal signal transduction: a hypothetical model for bipolar affective disorder. Life Sci 1989;45:1413-1426.
106. Altschule MD, Siegel EP, Henneman DF. Blood glutathione level in mental disease before and after treatment. Arch Psychiatry 1955;71:69-74.
107. Kuloglu M, Ustundag B, Atmaca M, et al. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct 2002;20:171-175.
108. Hoffer A, Walker M. Orthomolecular Nutrition. New Canaan, CT: Keats Publishing; 1978.
109. Milner G. Ascorbic acid in chronic psychiatric patients-a controlled trial. Br J Psychiatry 1963;109:294-299.
110. Naylor GJ, Smith AH. Vanadium: a possible aetiological factor in manic depressive illness. Psychol Med 1981;11:249-256.
111. Kay DS, Naylor GJ, Smith AH, Greenwood C. The therapeutic effect of ascorbic acid and EDTA in manic-depressive psychosis: double-blind comparisons with standard treatments. Psychol Med 1984;14:533-539.
112. Gosling RH, Kerry RJ, Owen G. Vitamin E ineffective in recurrent psychosis. Lancet 1971;2:1094.
113. Muller DP. Vitamin E - its role in neurological function. Postgrad Med J 1986;62:107-112.
114. Werbach MR. Nutritional Influences on Mental Illness. Tarzana, CA: Third Line Press; 1991.
115. Alpert JE, Mischoulon D, Nierenberg AA, Fava M. Nutrition and depression: focus on folate. Nutrition 2000;16:544-546.
116. Hashimoto R, Ozaki N, Ohta T, et al. The plasma tetrahydrobiopterin levels in patients with affective disorders. Biol Psychiatry 1990;28:526-528.
117. Hitzemann R, Mark C, Hirschowitz J, Garver D. Characteristics of phospholipid methylation in human erythrocyte ghosts: relationship(s) to the psychoses and affective disorders. Biol Psychiatry 1985;20:397-407.
118. Lipinski JF, Cohen BM, Frankenburg F, et al. Open trial of S-adenosylmethionine for treatment of depression. Am J Psychiatry 1984;141:448-450.
119. Goggans FC. A case of mania secondary to vitamin B 12 deficiency. Am J Psychiatry 1984;141:300-301.
120. Growdon JH, Wurtman RJ. Dietary influences on the synthesis of neurotransmitters in the brain. Nutr Rev 1979;37:129-136.
121. Bunney WE Jr, Davis JM. Norepinephrine in depressive reactions. A review. Arch Gen Psychiatry 1965;13:483-494.
122. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965;122:509-522.
123. Prange AJ Jr, Wilson IC, Lynn CW, et al. L-tryptophan in mania. Contribution to a permissive hypothesis of affective disorders. Arch Gen Psychiatry 1974;30:56-62.
124. Murphy DL, Baker M, Goodwin FK, et al. L-tryptophan in affective disorders: indoleamine changes and differential clinical effects. Psychopharmacologia 1974;34:11-20.
125. Chouinard G, Young SN, Annable L. A controlled clinical trial of L-tryptophan in acute mania. Biol Psychiatry 1985;20:546-557.
126. Chambers CA, Naylor GJ. A controlled trial of L-tryptophan in mania. Br J Psychiatry 1978;132:555-559.
127. Brewerton TD, Reus VI. Lithium carbonate and L-tryptophan in the treatment of bipolar and schizoaffective disorders. Am J Psychiatry 1983;140:757-760.
128. Beitman BD, Dunner DL. L-Tryptophan in the maintenance treatment of bipolar II manicdepressive illness. Am J Psychiatry 1982;139:1498-1499.
129. Chouinard G, Young SN, Annable L, Sourkes TL. Tryptophan-nicotinamide, imipramine and their combination in depression. A controlled study. Acta Psychiatr Scand 1979;59:395-414.
130. nd ed. Tarzana, CA: Third Line Press; 1993.
131. Byerley WF, Judd LL, Reimherr FW, Grosser BI. 5-Hydroxytryptophan: a review of its antidepressant efficacy and adverse effects. J Clin Psychopharmacol 1987;7:127-137.
132. Zmilacher K, Battegay R, Gastpar M. L-5-hydroxytryptophan alone and in combination with a peripheral decarboxylase inhibitor in the treatment of depression. Neuropsychobiology 1988;20:28-35.
133. van Praag HM. Management of depression with serotonin precursors. Biol Psychiatry 1981;16:291-310.
134. No authors listed. 5-Hydroxytryptophan (Monograph). In: Czap K, Miller AL, Head KA, eds. Alternative Medicine Review Monographs, Volume One. Dover, ID: Thorne Research; 2002.
135. Kaplan BJ, Simpson JS, Ferre RC, et al. Effective mood stabilization with a chelated mineral supplement: an open-label trial in bipolar disorder. J Clin Psychiatry 2001;62:936-944.
136. Popper CW. Do vitamins or minerals (apart from lithium) have mood-stabilizing effects? J Clin Psychiatry 2001;62:933-935.
137. Simmons M. Nutritional approach to bipolar disorder. J Clin Psychiatry 2003;64:338.
138. Neil JF, Himmelhoch JM, Mallinger AG, et al. Caffeinism complicating hypersomnic depressive episodes. Compr Psychiatry 1978;19:377-385.
139. Weyerer S, Kupfer B. Physical exercise and psychological health. Sports Med 1994;17:108-116.
140. Heninger GR, Mueller PS. Carbohydrate metabolism in mania before and after lithium carbonate treatment. Arch Gen Psychiatry 1970;23:310-319.
141. Hibbeln JR, Salem N Jr. Dietary polyunsaturated fatty acids and depression: when cholesterol does not satisfy. Am J Clin Nutr 1995;62:1-9.
142. Wright JV. Lithium, part 1: protect and renew your brain. Townsend Letter 2004;Feb/March:78-81.